Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

DGAP-News: STRATEC MIT DYNAMISCHEM WACHSTUM IN DEN ERSTEN NEUN MONATEN 2019
DGAP-News: STRATEC MIT DYNAMISCHEM WACHSTUM IN DEN ERSTEN NEUN MONATEN 2019
DGAP-News: STRATEC MIT DYNAMISCHEM WACHSTUM IN DEN ERSTEN NEUN MONATEN 2019
DGAP-News: STRATEC SHOWS DYNAMIC GROWTH IN FIRST NINE MONTHS OF 2019
DGAP-News: STRATEC SHOWS DYNAMIC GROWTH IN FIRST NINE MONTHS OF 2019
DGAP-News: STRATEC SHOWS DYNAMIC GROWTH IN FIRST NINE MONTHS OF 2019
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
DGAP-News: Fresenius Medical Care appoints Dr. Frank Maddux to Management Board, makes Global Chief Medical Officer a board position
DGAP-News: Fresenius Medical Care appoints Dr. Frank Maddux to Management Board, makes Global Chief Medical Officer a board position
DGAP-News: Fresenius Medical Care appoints Dr. Frank Maddux to Management Board, makes Global Chief Medical Officer a board position
DGAP-News: Fresenius Medical Care erweitert Vorstand mit Berufung von Global Chief Medical Officer Dr. Frank Maddux
DGAP-News: Fresenius Medical Care erweitert Vorstand mit Berufung von Global Chief Medical Officer Dr. Frank Maddux
DGAP-News: Fresenius Medical Care erweitert Vorstand mit Berufung von Global Chief Medical Officer Dr. Frank Maddux
DGAP-News: Fresenius Medical Care again delivers strong organic growth in the third quarter
DGAP-News: Fresenius Medical Care again delivers strong organic growth in the third quarter
DGAP-News: Fresenius Medical Care again delivers strong organic growth in the third quarter
DGAP-News: Fresenius Medical Care erzielt auch im dritten Quartal starkes organisches Wachstum
DGAP-News: Fresenius Medical Care erzielt auch im dritten Quartal starkes organisches Wachstum
DGAP-News: Fresenius Medical Care erzielt auch im dritten Quartal starkes organisches Wachstum
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
DGAP-Adhoc: Carl Zeiss Meditec erzielt EBIT-Marge von 18,1% im Geschäftsjahr 2018/19
DGAP-Adhoc: Carl Zeiss Meditec erzielt EBIT-Marge von 18,1% im Geschäftsjahr 2018/19
DGAP-Adhoc: Carl Zeiss Meditec erzielt EBIT-Marge von 18,1% im Geschäftsjahr 2018/19
DGAP-Adhoc: Carl Zeiss Meditec erzielt EBIT-Marge von 18,1% im Geschäftsjahr 2018/19
DGAP-Adhoc: Carl Zeiss Meditec erzielt EBIT-Marge von 18,1% im Geschäftsjahr 2018/19
DGAP-Adhoc: Carl Zeiss Meditec erzielt EBIT-Marge von 18,1% im Geschäftsjahr 2018/19
DGAP-Adhoc: Carl Zeiss Meditec achieves EBIT margin of 18.1% in fiscal year 2018/19
DGAP-Adhoc: Carl Zeiss Meditec achieves EBIT margin of 18.1% in fiscal year 2018/19
DGAP-Adhoc: Carl Zeiss Meditec achieves EBIT margin of 18.1% in fiscal year 2018/19
DGAP-Adhoc: Carl Zeiss Meditec achieves EBIT margin of 18.1% in fiscal year 2018/19
DGAP-Adhoc: Carl Zeiss Meditec achieves EBIT margin of 18.1% in fiscal year 2018/19
DGAP-Adhoc: Carl Zeiss Meditec achieves EBIT margin of 18.1% in fiscal year 2018/19
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
Form 8.3 - The Vanguard Group, Inc.: Allergan plc